Understanding the link between BCR-ABL, NEAT1, MYC, and the sensitivity of CML cells to Imatinib will provide further insight into the mechanisms of Imatinib resistance and ultimately lead to a way to circumvent it. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.